Objectives Temporary, percutaneous peripheral nerve stimulation (PNS) has been shown to provide analgesia for acute postoperative pain, postamputation pain, and low back pain. The implanted device stimulates the neural target for up to 60 days at which point the leads are extracted. Patients have demonstrated prolonged analgesia continuing after extraction of the leads. The purpose of this case series is to demonstrate peripheral neural targets that could feasibly be used to treat various pain syndromes prevalent in the oncologic population. Materials and Methods A temporary, percutaneous PNS was implanted under ultrasound guidance in 12 oncologic chronic pain patients seen in an outpatient pain clinic who had failed medical and/or interventional management. The device was implanted for up to 60 days. Clinical progress of pain and functional capacity was monitored through regular clinical visits. Results The case series presents seven successful cases of implementation of the PNS to treat oncologic pain. Three of these cases demonstrate targeting of proximal spinal nerves to treat truncal neuropathic pain and lumbar radicular pain. The four remaining cases demonstrate successful targeting of other peripheral nerves and brachial plexus. We also share five failed cases without adequate pain relief with PNS. Conclusions PNS has potential uses in the treatment of oncologic pain. Further high‐quality studies should be designed to further elucidate use of the PNS to treat oncologic pain.

No abstract

No abstract

No abstract

No abstract

No abstract

intestine preventing LPS-mediated endotoxemia. In this study, we sought to determine if gestational diabetes is associated with changes in these maternal and neonatal serum markers. STUDY DESIGN: Paired maternal and neonatal (cord blood) serum samples (n¼151) were obtained from our biobank repository. Gestational diabetes was diagnosed using Carpenter-Coustan glucose tolerance test cutoffs. Serum levels of LPS, EndoCAb-IgM, and GLP-2 were measured by ELISA. IL-6 and TNF-alpha were measured using a commercially available Milliplex assay. Results were stratified by diabetes diagnosis (non-diabetic n¼112, GDMA1 n¼11 and GDMA2 n¼28). RESULTS: Compared with non-diabetic gravidae, women with GDMA1 had lower serum levels of endoCAb-IgM (97.25 vs. 81.68 MMU/mL, p< 0.05) and neonates of women with GMDA1 had lower cord blood serum levels of GLP-2 (7.73 vs. 0.74 ng/mL, p< 0.05). Compared with non-diabetic gravidae, women with GDMA2 had lower levels of IL-6 (69.27 vs. 32.70 pg/mL, p< 0.05) and higher serum levels of TNF-alpha (6.15 vs. 7.97 pg/mL, p< 0.05). CONCLUSION: Lower endoCAb-IgM is associated with metabolic endotoxemia and may be exacerbated by gestational diabetes. We have previously shown that higher levels of GLP-2 may be protective of endotoxemia with excess gestational weight gain. Given the decrease in this peptide which is important for gut integrity in the neonate, it is possible that exposure to maternal diabetes could be associated with an increased susceptibility to endotoxemia.